Critical Ill PatientsNCT07057154
Glycated Hbg Index and RDW as Prognstic Indicator in Critical Ill Patients
An observational study of Critical Ill Patients, run by Assiut University.
Trial summary
The aim of this study was to evaluate the impact of GHI and RDW as prognostic indicator in critically ill Patients. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Critical Ill Patients
- What is being tested?
- Hbg and RDW
- Type of treatment
- Medical device
- How many people
- 97 participants
- Where
- No sites listed yet
- Study dates
- 5 Jul 2025to 2 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Adult, Older adult
Study population: All patients except patients in exculcion critira
Who may be able to join
- patients admitted to Critical and Intermediate Care Units in Internal Medicine Department after history taking, examination and diagnosis
- diabtic Patients 3-animic Patients
Who cannot join
- Patients under 18 years of age
- ICU stay < 24 h
- patients without HbA1c, FBG, or RDW data or anything's that's affect the HbA1c .
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Glycatetd Hemoglobin Index and Red Cell Distribution Width as Prognstic Indicator in Critical Ill Patients
The aim of this study was to evaluate the impact of GHI and RDW as prognostic indicator in critically ill Patients.
Read the detailed description
Primary (Main): determine the levels of the GHI And RDW In Critically Ill Patients at Critical and intermediate care units.
- Secondary (Subsidiary): Evaluate the prognostic significance of these parameters on patient outcomes, such as overall survival, progression-free survival, response to treatment.
- Conditions
- Critical Ill Patients
- Being tested
- Hbg and RDW
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hbg and RDWDevice
Hbg and RDW as prognstic indicator in critical ill patients
What is being measured
The primary outcome is the main question the study is designed to answer.
Glycated Hemoglobin level
Measurement of Hb level in all patients upon ICU admission.
Measured: Baseline
Red Cell Distribution Width (RDW)
Measurement of RDW in all patients upon ICU admission.
Measured: baseline
Hemoglobin (Hb) Level
Measurement of Hb level in all patients upon ICU admission.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start5 Jul 2025 (estimated)
- Primary completion29 Aug 2026 (estimated)
- Study completion2 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical Ill PatientsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 97 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rania Moukhter aziz aldean, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07057154
- Sponsor's protocol ID
- Rule of HBGA1C in critical ill
- Status last verified
- Jun 2025
- First submitted
- 29 May 2025
- Last updated
- 9 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Glycatetd Hemoglobin Index and Red Cell Distribution Width as Prognstic Indicator in Critical Ill Patients
- ClinicalTrials.gov ID
- NCT07057154
- Acronym / sponsor ID
- Rule of HBGA1C in critical ill
- Conditions
- Critical Ill Patients
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 97 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 5 Jul 2025 (estimated)
- Primary completion
- 29 Aug 2026 (estimated)
- Study completion
- 2 Dec 2026 (estimated)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to evaluate the impact of GHI and RDW as prognostic indicator in critically ill Patients.
Detailed description
Primary (Main): determine the levels of the GHI And RDW In Critically Ill Patients at Critical and intermediate care units.
- Secondary (Subsidiary): Evaluate the prognostic significance of these parameters on patient outcomes, such as overall survival, progression-free survival, response to treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients except patients in exculcion critira
Key inclusion criteria (2 listed)
- patients admitted to Critical and Intermediate Care Units in Internal Medicine Department after history taking, examination and diagnosis
- diabtic Patients 3-animic Patients
Key exclusion criteria (3 listed)
- Patients under 18 years of age
- ICU stay < 24 h
- patients without HbA1c, FBG, or RDW data or anything's that's affect the HbA1c .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hbg and RDWHbg and RDW as prognstic indicator in critical ill patients | Device | – |
Primary outcome
Glycated Hemoglobin level
Time frame: Baseline
Measurement of Hb level in all patients upon ICU admission.
Red Cell Distribution Width (RDW)
Time frame: baseline
Measurement of RDW in all patients upon ICU admission.
Hemoglobin (Hb) Level
Time frame: baseline
Measurement of Hb level in all patients upon ICU admission.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2025.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes
Related trials for Critical Ill Patients
Not yet recruitingObservational study
Ultrasound-Calibrated Pulse Contour Cardiac Output Monitoring: Value and Accuracy in Hemodynamic Care
Sepsis, Circulatory Instability
RecruitingObservational study
Comparison of PPV and LVOT VTI During Passive Leg Raising to Predict Fluid Responsiveness
Hemodynamic Instability, Hypovolemia
RecruitingPhase 4
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
Severe Infection
RecruitingObservational study
Respiratory Physiotherapy and Inflammatory Biomarkers in Critically Ill Patients With Pneumonia
Pneumonia, Critical Illness
RecruitingPhase 4
Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Acute Kidney Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Critical Ill Patients, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rania Moukhter Aziz eldeam (+201022004702, Moukhterrania@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glycated Hemoglobin level (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025.